A Virus-Like Particle (VLP) Vaccine Displaying Zika Envelope (E) Protein CD Loop Antigen Elicits Protective and Specific Immune Response in a Murine Model

6/20/2019 — 6/24/2019

Poster presented at ASM Microbe 2019


Zika virus (ZIKV) is a mosquito-borne flavivirus associated with Congenital Zika Syndrome (CZS), which comprises a wide range of congenital abnormalities in fetuses and infants infected with ZIKV before birth (1 and 2). In a small number of patients, ZIKV infection is strongly associated with the neurological autoimmune disorder Gullian Barré Syndrome (GBS) (3). To date, no vaccines or antiviral strategies are licensed for Zika Virus. Our aim is the development of a novel Zika vaccine candidate safe from antibody-dependent enhancement (ADE).